XENCOR INC (XNCR)
Health Care · engineered biotherapeutics / bispecific antibodies · NASDAQ
Xencor engineers multi-target bispecific antibodies and proprietary Fc domain technologies to redirect T cells against cancer and autoimmune disease.
What XENCOR INC does
Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses proprietary protein engineering capabilities to design XmAb drug candidates with improved properties and multi-target mechanisms of action, primarily leveraging engineered Fc domains and bispecific/multi-specific antibody formats. The company advances a portfolio of programs through Phase 1 and Phase 2 clinical studies, with applications including CD3 T-cell engaging bispecific antibodies, CD28 bispecific antibodies, and combination targets for inflammatory diseases.
Themes: ["immunoncology / T-cell engaging therapeutics","bispecific antibodies","autoimmune disease / inflammatory bowel disease","engineered antibodies","solid tumor targeting","cell therapy enhancement"]
Fundamentals
- Price$16.12 as of 2026-07-09 close
- Market cap$1.1B as of 2026-07-10
- 1-year return+72.7% as of 2026-07-09 close
- Net margin-177.1% as of 2026-07-10
- ROE-28.8% as of 2026-07-10
- Debt / equity0.21 as of 2026-07-10
- Revenue growth (YoY)-25.4% as of 2026-07-10
- Revenue CAGR (3y)-8.6% SEC XBRL
- Beta0.86 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: success depends on ongoing and planned clinical trials for a portfolio of early-stage programs, with uncertain timelines and regulatory approval outcomes","Partnership execution risk: company depends on collaborators' abilities to advance drug candidates and achieve milestones; loss of key partnerships could impact development","Competitive and financial pressure: significant competition in immunotherapy space combined with unprofitability and 25% YoY revenue decline creates sustainability risk"]
Competitors & peers
- Genmab (GMAB)
- Regeneron (REGN)
- Roche/Genentech
- Celldex Therapeutics
- Adicet Bio
- Affimed
- Arcus Biosciences
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.